The Bard PowerPort lawsuit is currently in active litigation with no settlements reached as of January 2026. There are 2,545 pending cases consolidated in a federal multidistrict litigation (MDL 3081) in the U.S. District Court for the District of Arizona, with the first bellwether trial””Cook v. Bard””scheduled to begin March 2, 2026. The case remains in the discovery phase, meaning document production, depositions, and testing of explanted devices are ongoing, but no global settlement has been announced between plaintiffs and defendants Bard Access Systems, Inc.
and Becton, Dickinson and Company (BD). The litigation has grown rapidly over the past year, with the number of pending cases nearly tripling from 891 claims in early 2025 to the current 2,545. For plaintiffs waiting to see resolution, the upcoming bellwether trials throughout 2026 represent the most significant development on the horizon. These test cases will provide both sides with critical information about how juries respond to the evidence, which typically influences settlement negotiations. A patient who experienced catheter fracture requiring emergency surgery, for example, may be watching these trials closely to gauge what compensation range their own case might fall into. This article covers the current MDL status and timeline, upcoming bellwether trial details, projected settlement amounts by injury tier, what injuries are alleged against the PowerPort device, and what plaintiffs should know about the litigation process moving forward.
Table of Contents
- How Many Cases Are Pending in the Bard PowerPort MDL?
- What Is the Bellwether Trial Schedule for 2026?
- What Settlement Amounts Are Attorneys Projecting?
- What Injuries Are Alleged in PowerPort Lawsuits?
- What Are the Limitations of Current Lawsuit Projections?
- Who Are the Defendants in the PowerPort Litigation?
- What Should Plaintiffs Expect Moving Forward?
- Conclusion
How Many Cases Are Pending in the Bard PowerPort MDL?
As of January 2026, there are 2,545 pending cases in the federal MDL, with 2,694 total cases filed since the litigation began. The cases are consolidated before U.S. District Judge David G. Campbell in Arizona, who has been managing the complex litigation through a series of case management orders. The 24th MDL Case Management Conference is scheduled for February 19, 2026, at 1:00 p.m. Arizona time via Zoom. The growth rate of this litigation is notable.
One year ago, approximately 891 claims were pending””meaning the docket has expanded by roughly 186% in twelve months. This surge reflects both increased awareness of potential device defects and the ongoing recruitment efforts by law firms across the country. For comparison, some medical device MDLs plateau after initial filings, while others continue to grow as more patients experience complications or learn about the litigation through advertising. The Bard PowerPort MDL falls into the latter category, suggesting that additional filings may continue throughout 2026. However, raw case numbers don’t tell the complete story. Not every filed case will proceed to resolution. Some claims may be dismissed for procedural reasons, lack of evidence, or failure to meet specific injury thresholds that would make litigation viable. Plaintiffs considering filing should understand that having a PowerPort device alone is insufficient””there must be documented evidence of injury causally linked to the device.
What Is the Bellwether Trial Schedule for 2026?
Six bellwether trials are scheduled throughout 2026, with the first””Cook v. Bard””set to begin March 2, 2026, and conclude by March 20, 2026. Case Management Order No. 38, issued August 20, 2025, confirmed this trial schedule, which extends through December 2026 with the final bellwether case. Additionally, the first Arizona state court trial is scheduled for August 3, 2026, providing a parallel track of litigation outside the federal MDL. Bellwether trials serve as test cases in mass tort litigation. Rather than trying thousands of individual cases, courts select representative plaintiffs whose circumstances reflect common allegations and injuries within the larger pool.
The outcomes””whether plaintiff verdicts, defense verdicts, or mistrials””provide crucial data points for both sides when evaluating the strength of their positions. If plaintiffs secure substantial verdicts, defendants face pressure to settle remaining cases. If defendants prevail, plaintiffs may need to reassess their expectations. The selected bellwether cases in the Bard PowerPort MDL cover three distinct injury categories: three cases involve infection injuries, two involve thrombus or occlusion injuries, and two (including one alternate) involve fracture injuries. This composition is intentional””it allows the litigation to test how juries respond to different theories of harm. A plaintiff whose PowerPort fractured and migrated, for instance, may see their case valued differently than one who developed sepsis from an infected port site. The bellwether outcomes will likely establish different valuation tiers based on injury type and severity.
What Settlement Amounts Are Attorneys Projecting?
No settlements have been reached in the Bard PowerPort litigation as of January 2026, but attorneys have offered projected ranges based on the alleged injuries and comparable medical device litigation. Overall estimates range from $10,000 to over $300,000 depending on individual circumstances, with most projections broken into tiers based on injury severity. Tier 1 cases involving severe injuries””such as cardiac punctures, pulmonary embolism, or stroke””are projected above $100,000. These represent the most serious complications, often requiring emergency intervention, extended hospitalization, or resulting in permanent damage. Tier 2 cases with moderate injuries, including deep vein thrombosis, catheter infections requiring treatment, and significant hematomas, are projected between $50,000 and $100,000. Less severe complications with full recovery would likely fall below these ranges.
These projections come with significant limitations. Until actual settlements occur or jury verdicts establish precedent, these figures remain speculative. The defendants may take aggressive positions at trial that result in lower (or no) recovery for plaintiffs. Conversely, strong plaintiff verdicts could push settlement values higher than current estimates. Individual case value also depends heavily on documentation””medical records proving the PowerPort caused the specific injury, evidence of resulting damages, and the plaintiff’s ability to establish the manufacturer’s fault. A plaintiff who waited months to seek treatment for symptoms, for example, may face arguments that their injuries stemmed from delay rather than the device itself.
What Injuries Are Alleged in PowerPort Lawsuits?
Plaintiffs in the Bard PowerPort litigation allege a range of injuries they attribute to defects in the implantable port catheter system. The primary allegations include catheter fractures, infections leading to sepsis, thrombosis (blood clot formation), organ and tissue punctures, pulmonary embolisms, and various internal injuries resulting from device failure or migration. Catheter fracture represents one of the most common allegations. The PowerPort system includes a flexible catheter that carries medication from the implanted port into a large vein. Plaintiffs allege this catheter is prone to cracking or breaking, potentially releasing fragments that can migrate through the bloodstream.
When catheter fragments travel to the heart or lungs, emergency surgery may be required for retrieval. One typical scenario involves a cancer patient who received chemotherapy through a PowerPort, only to experience sudden chest pain months later when imaging revealed a fractured catheter segment lodged near the heart. Infection allegations focus on the design and materials of the port itself, which plaintiffs claim create conditions conducive to bacterial colonization. Unlike a simple skin infection, port-related infections can become systemic, leading to sepsis””a life-threatening condition requiring intensive care. Thrombosis allegations similarly center on design features that plaintiffs claim promote clot formation around the catheter, potentially leading to deep vein thrombosis or, if clots break free, pulmonary embolism. The defendants dispute these characterizations, maintaining that their devices meet FDA requirements and that complications can occur with any implanted medical device.
What Are the Limitations of Current Lawsuit Projections?
Plaintiffs should approach settlement projections with caution because no global settlement exists and bellwether trials have not yet occurred. The figures circulating online””ranging from $10,000 to $300,000″”represent attorney estimates based on comparable litigation and anticipated outcomes, not guaranteed compensation. Until defendants agree to settlement terms or juries render verdicts, these numbers remain hypothetical. Several factors could result in individual recoveries falling below projections. Statute of limitations issues may bar some claims if too much time passed between injury discovery and filing. Weak medical documentation””particularly cases where the connection between the PowerPort and alleged injury is unclear””may result in dismissal or minimal recovery.
Pre-existing conditions that could explain symptoms independent of the device create additional hurdles. Plaintiffs who died from their injuries face wrongful death damage caps that vary by state. Additionally, mass tort litigation timelines are notoriously extended. Even with bellwether trials scheduled throughout 2026, global settlement negotiations””if they occur””could take months or years to finalize. Plaintiffs who need immediate financial relief should not rely on pending litigation. Those with pressing medical expenses may need to explore other options while their case proceeds, understanding that resolution may not come quickly regardless of the strength of their claims.
Who Are the Defendants in the PowerPort Litigation?
The named defendants are Bard Access Systems, Inc. and its parent company, Becton, Dickinson and Company (BD). Becton Dickinson acquired C.R. Bard in 2017, inheriting both the PowerPort product line and the legal exposure associated with it.
This corporate relationship matters because it determines the financial resources available for any eventual settlement and shapes litigation strategy. BD is a global medical technology company with substantial resources to mount an aggressive defense. The company has indicated it will defend the safety and efficacy of the PowerPort device through trial if necessary. Unlike some defendants in medical device litigation who quickly seek settlement to limit reputational damage, BD’s approach suggests plaintiffs should prepare for extended litigation rather than rapid resolution. This posture may shift depending on bellwether outcomes, but current indications point to a contested fight through 2026 and potentially beyond.
What Should Plaintiffs Expect Moving Forward?
The trajectory of the Bard PowerPort litigation depends heavily on the bellwether trial outcomes beginning in March 2026. If plaintiffs secure substantial verdicts, settlement pressure on defendants will increase, potentially accelerating global resolution. If defendants prevail or damages are lower than projected, the litigation may extend further as plaintiffs reassess their positions and strategies.
Plaintiffs currently in the MDL should expect continued activity throughout 2026″”discovery obligations, potential depositions, and the waiting period as bellwether cases proceed. Those considering filing should consult with attorneys experienced in medical device litigation to evaluate whether their injuries and documentation support a viable claim. The litigation remains active and growing, but individual outcomes will vary significantly based on injury severity, medical evidence, and the eventual resolution mechanism that emerges from the bellwether process.
Conclusion
The Bard PowerPort lawsuit remains in active litigation with 2,545 pending federal cases, no settlements to date, and the first bellwether trial scheduled for March 2026. The litigation has grown substantially over the past year, reflecting ongoing patient filings and increased awareness of alleged device defects. Projected settlement amounts range from $10,000 to over $300,000 depending on injury severity, though these figures remain speculative until actual resolutions occur.
Plaintiffs and potential claimants should monitor the upcoming bellwether trials closely, as these outcomes will likely shape the litigation’s direction and any eventual settlement framework. The 2026 trial schedule””covering infection, thrombosis, and fracture injury categories””will provide critical information about jury responses to different theories of harm. Those with documented PowerPort injuries should consult qualified legal counsel to evaluate their individual circumstances and determine whether participation in the ongoing litigation is appropriate for their situation.